Glynase PresTab Articles
Upjohn "Violated State Business Practice Laws"
8 August 1994
UPJOHN APPROVAL
13 December 1993
UPJOHN ANTI-HIV AGENTS IN PHASE II TRIALS
5 April 1993
RISK YEARS AHEAD FOR UPJOHNFOR UPJOHN
22 March 1993
Hoechst Roussel has no plans to market Glubate
22 June 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
UPJOHN UPDATES ON R&D PROGRESS
13 April 1992
Showing 1-7 of 7 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
